Overview

Effects of Celecoxib After Percutaneous Coronary Intervention

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
Several studies including ours have reported that celecoxib improves endothelium-dependent vasodilation and reduces inflammation and neointimal hyperplasia. Our hypothesis is that celecoxib may reduce the late luminal loss after coronary stent implantation (paclitaxel-eluting stent.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Celecoxib